Rhodamine 6G
| ToxCast Endpoints |
|---|
No ToxCast endpoints for intended target type: RNA
ToxCast Endpoints for intended target type: Protein
| Assay Name | Tissue | Target Gene ID | Target HGNC Symbol | Target UniProt ID | Response | AC50 value |
|---|---|---|---|---|---|---|
| CCTE_Deisenroth_5AR_NBTE_acceptor | Kidney | Activatory | 0.60 μM | |||
| STM_H9_OrnCyssISnorm_ratio | Inhibitory | 0.08 μM | ||||
| CCTE_GLTED_hTTR_0.125uM | 7276 | TTR | Loss | 32.20 μM | ||
| ATG_AP_1_CIS | Liver | 3725|2353 | JUN|FOS | P01100|P05412 | Activatory | 2.75 μM |
| ATG_NRF2_ARE_CIS | Liver | 4780 | NFE2L2 | Q16236 | Activatory | 0.13 μM |
| ATG_p53_CIS | Liver | 7157 | TP53 | P04637 | Inhibitory | 1.56 μM |
| NVS_MP_hPBR | Intestinal | 706 | TSPO | P30536 | Loss | 0.44 μM |
| NVS_NR_hTRa_Antagonist | 7067 | THRA | P10827 | Loss | 38.33 μM | |
| CCTE_GLTED_hDIO2 | 1734 | DIO2 | Loss | 153.82 μM | ||
| CCTE_GLTED_hDIO3 | 1735 | DIO3 | Loss | 156.55 μM | ||
| TOX21_AR_BLA_Antagonist_ratio | Kidney | 367 | AR | P10275 | Loss | 0.14 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 | Breast | 367 | AR | P10275 | Loss | 0.13 μM |
| TOX21_Aromatase_LUC_Antagonist | Breast | 1588 | CYP19A1 | P11511 | Loss | 0.15 μM |
| TOX21_ERa_BLA_Antagonist_ratio | Kidney | 2099 | ESR1 | P03372 | Loss | 0.10 μM |
| TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 | Breast | 2099 | ESR1 | P03372 | Loss | 0.19 μM |
| TOX21_GR_BLA_Agonist_ratio | Cervix | 2908 | NR3C1 | P04150 | Gain | 65.43 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 | Breast | 367 | AR | P10275 | Loss | 0.13 μM |
| TOX21_AP1_BLA_Agonist_ratio | Cervix | 3725|4029 | FOS|JUN|JUN | P05412|P01100|P05412 | Gain | 38.19 μM |
| TOX21_CAR_LUC_Antagonist | Liver | 9970 | NR1I3 | Q14994 | Loss | 45.94 μM |
| TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 | Breast | 2099 | ESR1 | P03372 | Loss | 0.14 μM |
| TOX21_ERR_LUC_Antagonist | Kidney | 2101 | ESRRA | P11474 | Loss | 0.11 μM |
| TOX21_PGC_ERR_LUC_Antagonist | Kidney | 2101 | ESRRA | P11474 | Loss | 0.13 μM |
| TOX21_ERb_BLA_Antagonist_ratio | Kidney | 2100 | ESR2 | Q92731 | Loss | 0.31 μM |
| TOX21_PR_BLA_Antagonist_ratio | Kidney | 5241 | PGR | P06401 | Loss | 44.56 μM |
| TOX21_PXR_LUC_Agonist | Liver | 8856 | NR1I2 | O75469 | Gain | 1.46 μM |
| TOX21_p450_CYP3A4_Antagonist | 1576 | CYP3A4 | P08684 | Loss | 1.17 μM | |
| TOX21_p450_CYP1A2_Antagonist | 1544 | CYP1A2 | P05177 | Loss | 36.27 μM | |
| TOX21_AChE_ms_Antagonist | 43 | ACHE | P22303 | Loss | 74.86 μM | |
| TOX21_hERG_U2OS_Antagonist | Bone | 3757 | KCNH2 | Q12809 | Loss | 2.77 μM |
| TOX21_AR_BLA_Antagonist_ratio | Kidney | 367 | AR | P10275 | Loss | 0.14 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881 | Breast | 367 | AR | P10275 | Loss | 0.13 μM |
| TOX21_Aromatase_LUC_Antagonist | Breast | 1588 | CYP19A1 | P11511 | Loss | 0.15 μM |
| TOX21_ERa_BLA_Antagonist_ratio | Kidney | 2099 | ESR1 | P03372 | Loss | 0.09 μM |
| TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 | Breast | 2099 | ESR1 | P03372 | Loss | 0.22 μM |
| TOX21_GR_BLA_Antagonist_ratio | Cervix | 2908 | NR3C1 | P04150 | Loss | 38.32 μM |
| TOX21_VDR_BLA_Antagonist_ratio | Kidney | 7421|1591 | CYP24A1|VDR | Q07973|P11473 | Loss | 39.08 μM |
| TOX21_VDR_BLA_Antagonist_ch1 | Kidney | Gain | 35.81 μM | |||
| TOX21_VDR_BLA_Antagonist_ch2 | Kidney | Loss | 62.82 μM | |||
| TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 | Breast | 367 | AR | P10275 | Loss | 0.13 μM |
| TOX21_AP1_BLA_Agonist_ratio | Cervix | 3725|4029 | FOS|JUN|JUN | P05412|P01100|P05412 | Gain | 55.39 μM |
| TOX21_CAR_LUC_Antagonist | Liver | 9970 | NR1I3 | Q14994 | Loss | 53.74 μM |
| TOX21_ERa_LUC_VM7_Antagonist_0.1nM_E2 | Breast | 2099 | ESR1 | P03372 | Loss | 0.17 μM |
| TOX21_ERR_LUC_Antagonist | Kidney | 2101 | ESRRA | P11474 | Loss | 0.11 μM |
| TOX21_PGC_ERR_LUC_Antagonist | Kidney | 2101 | ESRRA | P11474 | Loss | 0.09 μM |
| TOX21_ERb_BLA_Antagonist_ratio | Kidney | 2100 | ESR2 | Q92731 | Loss | 0.33 μM |
| TOX21_PR_BLA_Antagonist_ratio | Kidney | 5241 | PGR | P06401 | Loss | 45.92 μM |
| TOX21_PXR_LUC_Agonist | Liver | 8856 | NR1I2 | O75469 | Gain | 1.38 μM |
| TOX21_p450_CYP3A4_Antagonist | 1576 | CYP3A4 | P08684 | Loss | 1.45 μM | |
| TOX21_AChE_ms_Antagonist | 43 | ACHE | P22303 | Loss | 53.44 μM | |
| TOX21_hERG_U2OS_Antagonist | Bone | 3757 | KCNH2 | Q12809 | Loss | 3.01 μM |
No ToxCast endpoints for intended target type: Molecular Messengers
ToxCast Endpoints for intended target type: Pathway
| Assay Name | Tissue | Target Gene ID | Target HGNC Symbol | Target UniProt ID | Response | AC50 value |
|---|---|---|---|---|---|---|
| UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Antagonist | Bone | 367 | AR | P10275 | Loss | 0.75 μM |
| ACEA_ER_80hr | Breast | 2099 | ESR1 | P03372 | Gain | 0.04 μM |
| OT_AR_ARSRC1_0960 | Kidney | 6714|367 | AR|SRC | P12931|P10275 | Gain | 0.55 μM |
| OT_ER_ERaERa_1440 | Kidney | 2099 | ESR1 | P03372 | Gain | 62.31 μM |
| OT_ER_ERaERb_0480 | Kidney | 2100|2099 | ESR2|ESR1 | Q92731|P03372 | Gain | 71.27 μM |
| OT_ER_ERbERb_0480 | Kidney | 2100 | ESR2 | Q92731 | Gain | 55.07 μM |
| OT_ER_ERbERb_1440 | Kidney | 2100 | ESR2 | Q92731 | Gain | 76.39 μM |
| OT_FXR_FXRSRC1_0480 | Kidney | 6714|9971 | NR1H4|SRC | P12931|Q96RI1 | Gain | 1.36 μM |
| OT_NURR1_NURR1RXRa_0480 | Kidney | 4929|6256 | NR4A2|RXRA | P19793|P43354 | Gain | 0.60 μM |
| OT_NURR1_NURR1RXRa_1440 | Kidney | 4929|6256 | NR4A2|RXRA | P19793|P43354 | Gain | 0.77 μM |
| ACEA_AR_antagonist_80hr | Prostate | 367 | AR | P10275 | Loss | 0.04 μM |
| TOX21_ERa_BLA_Agonist_ch1 | Kidney | Loss | 65.92 μM | |||
| TOX21_GR_BLA_Agonist_ch1 | Cervix | Loss | 37.66 μM | |||
| TOX21_ARE_BLA_Agonist_ch2 | Liver | Gain | 0.09 μM | |||
| TOX21_ARE_BLA_Agonist_ratio | Liver | 4780 | NFE2L2 | Q16236 | Gain | 0.11 μM |
| TOX21_p53_BLA_p1_ch1 | Intestinal | Loss | 39.62 μM | |||
| TOX21_p53_BLA_p1_ratio | Intestinal | 7157 | TP53 | P04637 | Gain | 48.26 μM |
| TOX21_ERa_BLA_Antagonist_ch1 | Kidney | Gain | 0.15 μM | |||
| TOX21_ERa_BLA_Antagonist_ch2 | Kidney | Loss | 0.09 μM | |||
| TOX21_AR_BLA_Antagonist_ch2 | Kidney | Loss | 0.17 μM | |||
| TOX21_p53_BLA_p4_ch1 | Intestinal | Loss | 35.85 μM | |||
| TOX21_p53_BLA_p4_ratio | Intestinal | 7157 | TP53 | P04637 | Gain | 44.49 μM |
| TOX21_NFkB_BLA_agonist_ch1 | Cervix | Loss | 71.84 μM | |||
| TOX21_AP1_BLA_Agonist_ch1 | Cervix | Loss | 49.26 μM | |||
| TOX21_AP1_BLA_Agonist_ch2 | Cervix | Gain | 38.19 μM | |||
| TOX21_TSHR_HTRF_Agonist_ch2 | Kidney | Gain | 57.18 μM | |||
| TOX21_TSHR_HTRF_Antagonist_ch1 | Kidney | Gain | 42.21 μM | |||
| TOX21_TSHR_wt_HTRF_Agonist_ch2 | Kidney | Gain | 57.86 μM | |||
| TOX21_TSHR_wt_HTRF_Agonist_ratio | Kidney | 7253 | TSHR | Gain | 45.94 μM | |
| TOX21_HRE_BLA_Agonist_ch1 | Cervix | Loss | 44.75 μM | |||
| TOX21_ERb_BLA_Antagonist_ch2 | Kidney | Loss | 0.53 μM | |||
| TOX21_PR_BLA_Antagonist_ch2 | Kidney | Loss | 56.92 μM | |||
| TOX21_ERa_BLA_Agonist_ch1 | Kidney | Loss | 66.56 μM | |||
| TOX21_GR_BLA_Agonist_ch1 | Cervix | Loss | 57.01 μM | |||
| TOX21_ARE_BLA_Agonist_ratio | Liver | 4780 | NFE2L2 | Q16236 | Gain | 0.20 μM |
| TOX21_HSE_BLA_Agonist_ch1 | Cervix | Loss | 53.85 μM | |||
| TOX21_HSE_BLA_Agonist_ratio | Cervix | 3297 | HSF1 | Q00613 | Gain | 61.26 μM |
| TOX21_p53_BLA_p1_ratio | Intestinal | 7157 | TP53 | P04637 | Gain | 65.68 μM |
| TOX21_ERa_BLA_Antagonist_ch1 | Kidney | Gain | 0.06 μM | |||
| TOX21_ERa_BLA_Antagonist_ch2 | Kidney | Loss | 0.13 μM | |||
| TOX21_FXR_BLA_Antagonist_ch1 | Kidney | Gain | 0.64 μM | |||
| TOX21_GR_BLA_Antagonist_ch2 | Cervix | Loss | 33.34 μM | |||
| TOX21_PPARd_BLA_Antagonist_ch2 | Kidney | Loss | 59.85 μM | |||
| TOX21_AR_BLA_Antagonist_ch1 | Kidney | Gain | 0.43 μM | |||
| TOX21_AR_BLA_Antagonist_ch2 | Kidney | Loss | 0.13 μM | |||
| TOX21_p53_BLA_p2_ch1 | Intestinal | Loss | 34.35 μM | |||
| TOX21_p53_BLA_p3_ch1 | Intestinal | Loss | 33.84 μM | |||
| TOX21_p53_BLA_p4_ch1 | Intestinal | Loss | 40.97 μM | |||
| TOX21_p53_BLA_p4_ratio | Intestinal | 7157 | TP53 | P04637 | Gain | 35.77 μM |
| TOX21_AP1_BLA_Agonist_ch1 | Cervix | Loss | 56.90 μM | |||
| TOX21_AP1_BLA_Agonist_ch2 | Cervix | Gain | 53.71 μM | |||
| TOX21_TSHR_HTRF_Antagonist_ch1 | Kidney | Gain | 55.06 μM | |||
| TOX21_TSHR_wt_HTRF_Agonist_ch2 | Kidney | Gain | 54.47 μM | |||
| TOX21_TSHR_wt_HTRF_Agonist_ratio | Kidney | 7253 | TSHR | Gain | 46.08 μM | |
| TOX21_ERb_BLA_Antagonist_ch2 | Kidney | Loss | 0.23 μM | |||
| TOX21_PR_BLA_Antagonist_ch2 | Kidney | Loss | 64.71 μM |
ToxCast Endpoints for intended target type: Cellular
| Assay Name | Tissue | Response | AC50 value |
|---|---|---|---|
| CCTE_Harrill_HTTr_Viability_MCF7 | Breast | Gain | 0.16 μM |
| CCTE_Harrill_HTTr_Apoptosis_MCF7 | Breast | Gain | 0.05 μM |
| STM_H9_NormalizedViability | Loss | 0.12 μM | |
| ACEA_AR_agonist_AUC_viability | Prostate | Loss | 0.01 μM |
| ACEA_AR_antagonist_AUC_viability | Prostate | Loss | 0.01 μM |
| CCTE_Harrill_HTTr_Viability_MCF7 | Breast | Gain | 0.21 μM |
| CCTE_Harrill_HTTr_Apoptosis_MCF7 | Breast | Gain | 0.10 μM |
| TOX21_AR_BLA_Antagonist_viability | Kidney | Loss | 0.68 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability | Breast | Loss | 1.09 μM |
| TOX21_Aromatase_LUC_Antagonist_viability | Breast | Loss | 1.06 μM |
| TOX21_MMP_fitc | Liver | Gain | 2.40 μM |
| TOX21_p53_BLA_p1_viability | Intestinal | Loss | 64.38 μM |
| TOX21_PPARd_BLA_Agonist_viability | Kidney | Loss | 1.18 μM |
| TOX21_p53_BLA_p2_viability | Intestinal | Loss | 45.94 μM |
| TOX21_p53_BLA_p3_viability | Intestinal | Loss | 36.82 μM |
| TOX21_p53_BLA_p4_viability | Intestinal | Loss | 58.16 μM |
| TOX21_p53_BLA_p5_viability | Intestinal | Loss | 63.23 μM |
| TOX21_VDR_BLA_Agonist_viability | Kidney | Loss | 0.89 μM |
| TOX21_NFkB_BLA_agonist_viability | Cervix | Loss | 62.81 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability | Breast | Loss | 0.98 μM |
| TOX21_RXR_BLA_Agonist_viability | Kidney | Loss | 45.56 μM |
| TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability | Breast | Loss | 0.30 μM |
| TOX21_AP1_BLA_Agonist_viability | Cervix | Loss | 59.40 μM |
| TOX21_CAR_LUC_Agonist_viability | Liver | Loss | 1.78 μM |
| TOX21_CAR_LUC_Antagonist_viability | Liver | Loss | 1.83 μM |
| TOX21_ERR_LUC_viability | Kidney | Loss | 0.26 μM |
| TOX21_HDAC_LUC_Antagonist_viability | Colon | Loss | 45.94 μM |
| TOX21_PGC_ERR_LUC_viability | Kidney | Loss | 0.30 μM |
| TOX21_RT_HEK293_GLO_32hr_viability | Kidney | Loss | 1.75 μM |
| TOX21_RT_HEK293_GLO_40hr_viability | Kidney | Loss | 0.86 μM |
| TOX21_RT_HEPG2_GLO_16hr_viability | Liver | Loss | 33.01 μM |
| TOX21_RT_HEPG2_GLO_32hr_viability | Liver | Loss | 35.15 μM |
| TOX21_RT_HEPG2_GLO_40hr_viability | Liver | Loss | 39.90 μM |
| TOX21_PR_BLA_Agonist_viability | Kidney | Loss | 78.39 μM |
| TOX21_PR_BLA_Antagonist_viability | Kidney | Loss | 74.15 μM |
| TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability | Breast | Loss | 2.11 μM |
| TOX21_RT_HEPG2_GLO_24hr_viability | Liver | Loss | 32.19 μM |
| TOX21_PXR_LUC_Agonist_viability | Liver | Loss | 1.78 μM |
| TOX21_SBE_BLA_Antagonist_viability | Kidney | Loss | 34.01 μM |
| TOX21_SBE_BLA_Agonist_viability | Kidney | Loss | 39.66 μM |
| TOX21_AR_BLA_Antagonist_viability | Kidney | Loss | 0.77 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_10nM_R1881_viability | Breast | Loss | 1.38 μM |
| TOX21_Aromatase_LUC_Antagonist_viability | Breast | Loss | 1.79 μM |
| TOX21_MMP_fitc | Liver | Gain | 2.37 μM |
| TOX21_AhR_LUC_Agonist_viability | Liver | Loss | 2.63 μM |
| TOX21_FXR_BLA_agonist_viability | Kidney | Loss | 38.30 μM |
| TOX21_p53_BLA_p2_viability | Intestinal | Loss | 38.30 μM |
| TOX21_p53_BLA_p3_viability | Intestinal | Loss | 59.65 μM |
| TOX21_p53_BLA_p4_viability | Intestinal | Loss | 67.53 μM |
| TOX21_p53_BLA_p5_viability | Intestinal | Loss | 60.82 μM |
| TOX21_ESRE_BLA_Agonist_viability | Cervix | Loss | 38.32 μM |
| TOX21_NFkB_BLA_agonist_viability | Cervix | Loss | 61.85 μM |
| TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881_viability | Breast | Loss | 0.69 μM |
| TOX21_RXR_BLA_Agonist_viability | Kidney | Loss | 49.57 μM |
| TOX21_AR_LUC_MDAKB2_Agonist_3uM_Nilutamide_viability | Breast | Loss | 0.30 μM |
| TOX21_CAR_LUC_Agonist_viability | Liver | Loss | 2.11 μM |
| TOX21_CAR_LUC_Antagonist_viability | Liver | Loss | 1.56 μM |
| TOX21_ERR_LUC_viability | Kidney | Loss | 0.21 μM |
| TOX21_HRE_BLA_Agonist_viability | Cervix | Loss | 38.32 μM |
| TOX21_PGC_ERR_LUC_viability | Kidney | Loss | 0.18 μM |
| TOX21_RT_HEK293_GLO_32hr_viability | Kidney | Loss | 2.41 μM |
| TOX21_RT_HEK293_GLO_40hr_viability | Kidney | Loss | 0.95 μM |
| TOX21_PR_BLA_Agonist_viability | Kidney | Loss | 81.06 μM |
| TOX21_PR_BLA_Antagonist_viability | Kidney | Loss | 74.98 μM |
| TOX21_ERa_LUC_VM7_Agonist_10nM_ICI182780_viability | Breast | Loss | 2.01 μM |
| TOX21_PXR_LUC_Agonist_viability | Liver | Loss | 0.99 μM |
| TOX21_SBE_BLA_Antagonist_viability | Kidney | Loss | 35.49 μM |
| TOX21_SBE_BLA_Agonist_viability | Kidney | Loss | 35.91 μM |
No ToxCast endpoints for intended target type: Extracellular
DISCLAIMER
TICToK is a knowledgebase of chemicals found in tattoo inks, compiled from publicly available regulatory and scientific resources. The chemical classifications presented in this knowledgebase are derived from multiple publicly available resources and are provided solely for informational purposes, and they are neither authoritative nor binding. The authors bear no responsibility for any errors, omissions, or inconsistencies originating from these external sources. Users are advised to exercise independent judgment when interpreting chemical classifications and any other data provided in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.